All In Biotech

NDA 213872 · Bayer Hlthcare

Astepro Allergy

Azelastine Hydrochloride · Nasal

Last checked: Nov 19, 2026Latest source record: Oct 27, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2021

Jun 17, 2021

Approved uses

1

Original approval plus efficacy supplements

Registered trials

62

23 Phase 3, 1 recruiting

FAERS reports

1,427

646 serious, 76 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 17, 2021 Original approval · Type 8 - Partial Rx to OTC Switch LetterLabelReview
2 products under this application
  • ASTEPRO ALLERGY · AZELASTINE HYDROCHLORIDE 0.2055MG/SPRAY · SPRAY, METERED, NASAL · Over-the-counter
  • CHILDREN'S ASTEPRO ALLERGY · AZELASTINE HYDROCHLORIDE 0.2055MG/SPRAY · SPRAY, METERED, NASAL · Over-the-counter

Clinical trials

Interventional ClinicalTrials.gov studies with "Azelastine" as an intervention, any sponsor and status, largest first.

All 62 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective104
  • fatigue100
  • headache81
  • nausea74
  • diarrhoea73
  • dizziness60
  • dyspnoea54
  • pneumonia52
  • cough50
  • pain50
  • vomiting49
  • malaise47

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200413
20056
20068
200715
200825
200922
201072
201146
201240
20136
201417
201562
2016112
2017111
2018140
2019162
2020182
2021133
20225
202334
20245
2025195
202616

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 190 on PubMed

Sponsor: Bayer · Also marketed as Children'S Astepro Allergy

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.